Fig. 6
AZD7648 and olaparib combination has anti-tumour efficacy in PDX models. a AZD7648 induces tumour regression in combination with olaparib in HBCx-17 TNBC PDX (nude mice, n = 10; individual tumour spider plots for olaparib and combination groups). b AZD7648 induces tumour regression in combination with olaparib in CTG-703 ovarian PDX (nude mice, olaparib n = 4, other treatments n = 6). c AZD7648 induces tumour regression in combination with olaparib in OV2022 ovarian PDX (SCID mice, n = 8). d AZD7648 induces tumour regression in combination with olaparib in CTG-0828 NSCLC PDX (nude mice, vehicle n = 5, other treatments n = 3). e AZD7648 in combination with olaparib induces significant TGI in CTG-0149 H&N PDX (nude mice, vehicle n = 5, other treatments n = 3). All graphs represent geometric mean ± SEM. Corresponding mouse bodyweights and statistical analysis can be found in Supplementary Fig. 5B–F and Supplementary Table 3C. To assess tumour growth inhibition, one-tailed, two-sample, t-test with unequal variances was used and for tumour regression, one-sample t-test analysis
